Peripheral retinal dysfunction in patients taking vigabatrin

J. McDonagh, L. J. Stephen, Fiona M. Dolan, S. Parks, Gordon N. Dutton, K. Kelly, D. Keating, G. J. Sills

Research output: Contribution to journalArticle

Abstract

The objective of this research was to assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retinal function in vigabatrin-treated patients. Thirty-two adults who had taken vigabatrin for at least 3 years for localization-related epilepsy underwent WF-mfERG, ERG, logMar visual acuity and color vision evaluation, Humphrey visual field analysis (static perimetry), and funduscopy. The group was matched with a cohort of patients who had never received vigabatrin. Results were compared with a normative data set (120 drug-free controls) with respect to potential bilateral abnormalities in response timing. There were no significant differences between groups in visual acuity or color vision testing. Of the vigabatrin patients, 19 (59%) had bilateral visual field defects compared to none of the controls. Using WF-mfERG, all patients on vigabatrin with visual field defects showed abnormalities (100% sensitivity) and only 2 of the 13 patients without a field defect showed retinal abnormalities (86% specificity). WF-mfERG may be useful for detecting retinal pathology in patients taking vigabatrin. The majority of previous reports based on subjective testing may have underestimated the prevalence of peripheral retinal toxicity related to the drug.

Original languageEnglish
JournalNeurology
Publication statusPublished - 1 Dec 2003

Fingerprint

Vigabatrin
Visual Fields
Color Vision
Visual Acuity
Visual Field Tests
Partial Epilepsy
Drug and Narcotic Control
Research Design
Pathology
Research
Pharmaceutical Preparations

Keywords

  • peripheral retinal dysfunction
  • vigabatrin
  • vision science

Cite this

McDonagh, J., Stephen, L. J., Dolan, F. M., Parks, S., Dutton, G. N., Kelly, K., ... Sills, G. J. (2003). Peripheral retinal dysfunction in patients taking vigabatrin. Neurology.
McDonagh, J. ; Stephen, L. J. ; Dolan, Fiona M. ; Parks, S. ; Dutton, Gordon N. ; Kelly, K. ; Keating, D. ; Sills, G. J. / Peripheral retinal dysfunction in patients taking vigabatrin. In: Neurology. 2003.
@article{90f5b7c80d404110bbd7e5e596511c85,
title = "Peripheral retinal dysfunction in patients taking vigabatrin",
abstract = "The objective of this research was to assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retinal function in vigabatrin-treated patients. Thirty-two adults who had taken vigabatrin for at least 3 years for localization-related epilepsy underwent WF-mfERG, ERG, logMar visual acuity and color vision evaluation, Humphrey visual field analysis (static perimetry), and funduscopy. The group was matched with a cohort of patients who had never received vigabatrin. Results were compared with a normative data set (120 drug-free controls) with respect to potential bilateral abnormalities in response timing. There were no significant differences between groups in visual acuity or color vision testing. Of the vigabatrin patients, 19 (59{\%}) had bilateral visual field defects compared to none of the controls. Using WF-mfERG, all patients on vigabatrin with visual field defects showed abnormalities (100{\%} sensitivity) and only 2 of the 13 patients without a field defect showed retinal abnormalities (86{\%} specificity). WF-mfERG may be useful for detecting retinal pathology in patients taking vigabatrin. The majority of previous reports based on subjective testing may have underestimated the prevalence of peripheral retinal toxicity related to the drug.",
keywords = "peripheral retinal dysfunction, vigabatrin, vision science",
author = "J. McDonagh and Stephen, {L. J.} and Dolan, {Fiona M.} and S. Parks and Dutton, {Gordon N.} and K. Kelly and D. Keating and Sills, {G. J.}",
note = "Originally published in: Neurology (2003), 61 (12), pp.1690-1694.",
year = "2003",
month = "12",
day = "1",
language = "English",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins Ltd.",

}

McDonagh, J, Stephen, LJ, Dolan, FM, Parks, S, Dutton, GN, Kelly, K, Keating, D & Sills, GJ 2003, 'Peripheral retinal dysfunction in patients taking vigabatrin', Neurology.

Peripheral retinal dysfunction in patients taking vigabatrin. / McDonagh, J.; Stephen, L. J.; Dolan, Fiona M.; Parks, S.; Dutton, Gordon N.; Kelly, K.; Keating, D.; Sills, G. J.

In: Neurology, 01.12.2003.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peripheral retinal dysfunction in patients taking vigabatrin

AU - McDonagh, J.

AU - Stephen, L. J.

AU - Dolan, Fiona M.

AU - Parks, S.

AU - Dutton, Gordon N.

AU - Kelly, K.

AU - Keating, D.

AU - Sills, G. J.

N1 - Originally published in: Neurology (2003), 61 (12), pp.1690-1694.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The objective of this research was to assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retinal function in vigabatrin-treated patients. Thirty-two adults who had taken vigabatrin for at least 3 years for localization-related epilepsy underwent WF-mfERG, ERG, logMar visual acuity and color vision evaluation, Humphrey visual field analysis (static perimetry), and funduscopy. The group was matched with a cohort of patients who had never received vigabatrin. Results were compared with a normative data set (120 drug-free controls) with respect to potential bilateral abnormalities in response timing. There were no significant differences between groups in visual acuity or color vision testing. Of the vigabatrin patients, 19 (59%) had bilateral visual field defects compared to none of the controls. Using WF-mfERG, all patients on vigabatrin with visual field defects showed abnormalities (100% sensitivity) and only 2 of the 13 patients without a field defect showed retinal abnormalities (86% specificity). WF-mfERG may be useful for detecting retinal pathology in patients taking vigabatrin. The majority of previous reports based on subjective testing may have underestimated the prevalence of peripheral retinal toxicity related to the drug.

AB - The objective of this research was to assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retinal function in vigabatrin-treated patients. Thirty-two adults who had taken vigabatrin for at least 3 years for localization-related epilepsy underwent WF-mfERG, ERG, logMar visual acuity and color vision evaluation, Humphrey visual field analysis (static perimetry), and funduscopy. The group was matched with a cohort of patients who had never received vigabatrin. Results were compared with a normative data set (120 drug-free controls) with respect to potential bilateral abnormalities in response timing. There were no significant differences between groups in visual acuity or color vision testing. Of the vigabatrin patients, 19 (59%) had bilateral visual field defects compared to none of the controls. Using WF-mfERG, all patients on vigabatrin with visual field defects showed abnormalities (100% sensitivity) and only 2 of the 13 patients without a field defect showed retinal abnormalities (86% specificity). WF-mfERG may be useful for detecting retinal pathology in patients taking vigabatrin. The majority of previous reports based on subjective testing may have underestimated the prevalence of peripheral retinal toxicity related to the drug.

KW - peripheral retinal dysfunction

KW - vigabatrin

KW - vision science

M3 - Article

JO - Neurology

JF - Neurology

SN - 0028-3878

ER -

McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003 Dec 1.